Palvella Therapeutics, Inc. Common Stock
PVLAPalvella Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for dermatological and other dermatology-related diseases. It specializes in innovative topical treatments aimed at addressing unmet medical needs in skin-related conditions.
$92.41 -3.38 (-3.47%)
Company News
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORINâ„¢ 3.9% Rapamycin Anhydrous Gel (QTORINâ„¢ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies
Palvella Therapeutics reported positive Phase 2 trial results for QTORINâ„¢ rapamycin gel in treating cutaneous venous malformations, with 73% of participants showing improvement and no serious adverse events reported.
